KUROGRAFT
DEAD

Serial Number

77345125

Owner

Kuros Biosurgery AG

Attorney

Jody H. Drake

Filing Date

Dec 5, 2007

Add to watchlist:

No watchlists yet
View on USPTO

KUROGRAFT Trademark

Serial Number: 77345125 • Registration: 3882001

KUROGRAFT is a trademark filed by Kuros Biosurgery AG on December 5, 2007. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Kuros Biosurgery AG (8 trademarks)

Wagistrasse 25

Entity Type: 99

Trademark Details

Filing Date

December 5, 2007

Registration Date

November 30, 2010

Published for Opposition

February 9, 2010

Cancellation Date

July 7, 2017

Goods & Services

Cosmetic products, namely, implants, coatings, creams, gels, solutions, pastes, beads, microparticles, nanoparticles and cement, which contain hormones and/or growth factors to support restoration and reconstruction in reconstructive or cosmetic surgery; materials for permanent or temporary enlargement, filling, repair, stabilization, support and replication of endogenous soft tissue, in particular fatty tissue and muscle tissue, other than for medical purposes, namely, protein and/or peptide and/or polyalkylenoxide preparations; carrier materials of synthetic and/or natural origin for cosmetic purposes, namely, matrices, solutions, gels, pastes, microparticles, nanoparticles, beads and cements, in particular consisting of fibrin and/or polyethylene glycol for retention or increased release of peptides or proteins, in particular hormones and growth factors, i.e., substances which stimulate growth of an organism or maintain growth for use in reconstructive, regenerative, generative and cosmetic interventions for treatment of injured, diseased or degenerated tissue; pharmaceutical products and preparations, namely, protein and/or peptide preparations, in particular for locally supporting the formation or regeneration of missing or damaged body parts, in particular of hard or soft tissue, in particular skin or bone; pharmaceutical or medical formulations, namely, implants, coatings, creams, gels, solutions, pastes, beads, microparticles, nanoparticles and cements of synthetic and/or natural origin for medical purposes, namely, for use in reconstructive, regenerative, generative and cosmetic interventions for treatment of injured, diseased or degenerated tissue, in particular comprising fibrin and/or polyoxyalkyleneoxides, namely, polyethylene glycol for retention or sustained release of peptides, proteins and/or allograft materials, in particular hormones, growth factors and/or demineralized bone matrix, i.e., substances which stimulate growth of an organism or maintain growth; healthcare preparations, namely, implants, coatings, creams, gels, solutions, pastes, beads, microparticles, nanoparticles and cements for use in reconstructive, regenerative, generative and cosmetic interventions for treatment of injured, diseased or degenerated tissue; biomedical products and biotechnology products for medical purposes, namely, peptides and proteins like hormones and growth factors or allograft materials used to spur regrowth and formation and to repair tissue, namely, tissue of bone, skin, organs, tendons, ligament, cartilage; materials for medical purposes for permanent or temporary enlargement, filling, repair, stabilization, support and/or regeneration of hard or soft tissue, in particular bone, intervertebral disk, cartilage, fatty tissue and muscle tissue, namely, protein and/or peptide and/or polyalkylenoxide preparations; biocompatible permanent or temporary adhesives and sealants, in particular for human and animal organs, soft and hard tissue for medical purposes; biocompatible separating materials, namely, anti-adhesion materials for avoiding undesired adhesion of organs and/or soft parts for medical purposes; implants and transplants of human derived autologous or allograft materials; autologous and allograft soft tissue for cosmetic and medical purposes; autologous and allograft hard and soft tissue in particular bone for transplantation purposes, bone replacement, cartilage replacement, vessel replacement, tissue replacement and fatty tissue replacement

Artificial tissue replacement for restoring, maintaining and/or improving the function of diseased or damaged human or animal tissue (tissue engineering); synthetic implants, and transplants and modified implants and transplants, tissue, cells and/or molecules for replacing and/or for supporting the function of missing or damaged body parts; synthetic hard and soft tissue, in particular synthetic bone for transplantation purposes and diagnostic purposes, synthetic bone replacement, cartilage replacement, vessel replacement, tissue replacement and fatty tissue replacement; modified implants and transplants with engineered endogenous material, tissue, cells or molecules for replacing and/or for supporting the function of missing or damaged body parts

Filing History

CANCELLED SEC. 8 (6-YR)
Jul 7, 2017 C8..
REGISTERED-PRINCIPAL REGISTER
Nov 30, 2010 R.PR
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Oct 21, 2010 PCBG
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Oct 21, 2010 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 20, 2010 AITU
ASSIGNED TO PETITION STAFF
Oct 20, 2010 APET
NOTICE OF ALLOWANCE CANCELLED
Oct 19, 2010 IUCN
TEAS POST PUBLICATION AMENDMENT RECEIVED
Oct 19, 2010 EPPA
TEAS PETITION TO AMEND BASIS RECEIVED
Oct 19, 2010 TPAD
NOA MAILED - SOU REQUIRED FROM APPLICANT
May 4, 2010 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 9, 2010 NPUB
PUBLISHED FOR OPPOSITION
Feb 9, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 7, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 7, 2010 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 17, 2009 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 17, 2009 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 21, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jul 21, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jul 21, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 23, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 23, 2009 CRFA
ASSIGNED TO LIE
May 21, 2009 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
May 21, 2009 ERFR
EX PARTE APPEAL-INSTITUTED
May 21, 2009 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
May 21, 2009 JURT
EXPARTE APPEAL RECEIVED AT TTAB
May 21, 2009 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 21, 2008 GNFN
FINAL REFUSAL E-MAILED
Nov 21, 2008 GNFR
FINAL REFUSAL WRITTEN
Nov 21, 2008 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2008 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 7, 2008 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 25, 2008 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 25, 2008 GNSL
SUSPENSION LETTER WRITTEN
Sep 25, 2008 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 16, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 16, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 16, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 17, 2008 GNRN
NON-FINAL ACTION E-MAILED
Mar 17, 2008 GNRT
NON-FINAL ACTION WRITTEN
Mar 17, 2008 CNRT
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 14, 2008 PARI
ASSIGNED TO EXAMINER
Mar 14, 2008 DOCK
NOTICE OF PSEUDO MARK MAILED
Dec 11, 2007 MPMK
NEW APPLICATION ENTERED
Dec 10, 2007 NWAP